Ministry of Chemicals and Fertilizers : press release · 10 March 2026 · pibtracker filter

Bio Pharma SHAKTI scheme

PRID2237416 MinistryMinistry of Chemicals and Fertilizers : Released10 March 2026 Reading8 min

Posted On: 10 MAR 2026 1:33PM by PIB Delhi With a view to strengthening the domestic biopharmaceutical sector and enhancing global competitiveness in biologics and biosimilars, the Government has announced the Biopharma SHAKTI scheme with an outlay of ₹10,000 crore over five years with an objective to build a globally competitive domestic ecosystem for biologics and biosimilars to support affordable healthcare in India and enable India to emerge as a global biopharma manufacturing and innovation hub. India’s disease burden is observed to be shifting towards non-communicable diseases, like diabetes, cancer and autoimmune disorders. Biologic medicines are key to longevity and quality of life at affordable costs. To develop India as a global Biopharma manufacturing hub, an initiative like Biopharma SHAKTI for the biopharma sector is intended to benefit the Indian pharma industry in the following manner: i. The initiative aims to support domestic development and manufacturing of high-value biopharmaceutical products and medicines, reduce import dependence, and enhance India’s competitiveness in global biologics supply chain. ii. Expansion and strengthening of Biopharma-focused network through establishment of three new National Institutes of Pharmaceutical Education & Research (NIPERs) and upgradation of seven existing NIPERs to address growing requirement of specialised human resource in biopharma research, development, manufacturing and regulation. iii. Creation of large-scale clinical research ecosystem with a focus on improving India’s capacity to conduct advanced clinical trials. iv. The Central Drugs Standard Control Organisation (CDSCO) to be reinforced to strengthen regulatory framework which will enable faster, globally credible approvals by creation of a dedicated Scientific Review Cadre. It will reduce number of days currently being taken for regulatory approvals. v. The initiative focuses on early-stage innovation funding and structured equity support to help startups and industry take promising candidates from concept through key development milestones. This information was given by Minister of State for Chemicals and Fertilizers, Smt. Anupriya Patel, in a written reply in the Rajya Sabha today. ***** PC/PM (Release ID: 2237416) Visitor Counter : 3634 Read this release in: Urdu , हिन्दी Ministry of Chemicals and Fertilizers : Department of Pharmaceuticals Bio Pharma SHAKTI scheme Posted On: 10 MAR 2026 1:33PM by PIB Delhi With a view to strengthening the domestic biopharmaceutical sector and enhancing global competitiveness in biologics and biosimilars, the Government has announced the Biopharma SHAKTI scheme with an outlay of ₹10,000 crore over five years with an objective to build a globally competitive domestic ecosystem for biologics and biosimilars to support affordable healthcare in India and enable India to emerge as a global biopharma manufacturing and innovation hub. India’s disease burden is observed to be shifting towards non-communicable diseases, like diabetes, cancer and autoimmune disorders. Biologic medicines are key to longevity and quality of life at affordable costs. To develop India as a global Biopharma manufacturing hub, an initiative like Biopharma SHAKTI for the biopharma sector is intended to benefit the Indian pharma industry in the following manner: i. The initiative aims to support domestic development and manufacturing of high-value biopharmaceutical products and medicines, reduce import dependence, and enhance India’s competitiveness in global biologics supply chain. ii. Expansion and strengthening of Biopharma-focused network through establishment of three new National Institutes of Pharmaceutical Education & Research (NIPERs) and upgradation of seven existing NIPERs to address growing requirement of specialised human resource in biopharma research, development, manufacturing and regulation. iii. Creation of large-scale clinical research ecosystem with a focus on improving India’s capacity to conduct advanced clinical trials. iv. The Central Drugs Standard Control Organisation (CDSCO) to be reinforced to strengthen regulatory framework which will enable faster, globally credible approvals by creation of a dedicated Scientific Review Cadre. It will reduce number of days currently being taken for regulatory approvals. v. The initiative focuses on early-stage innovation funding and structured equity support to help startups and industry take promising candidates from concept through key development milestones. This information was given by Minister of State for Chemicals and Fertilizers, Smt. Anupriya Patel, in a written reply in the Rajya Sabha today. ***** PC/PM (Release ID: 2237416) With a view to strengthening the domestic biopharmaceutical sector and enhancing global competitiveness in biologics and biosimilars, the Government has announced the Biopharma SHAKTI scheme with an outlay of ₹10,000 crore over five years with an objective to build a globally competitive domestic ecosystem for biologics and biosimilars to support affordable healthcare in India and enable India to emerge as a global biopharma manufacturing and innovation hub. India’s disease burden is observed to be shifting towards non-communicable diseases, like diabetes, cancer and autoimmune disorders. Biologic medicines are key to longevity and quality of life at affordable costs. To develop India as a global Biopharma manufacturing hub, an initiative like Biopharma SHAKTI for the biopharma sector is intended to benefit the Indian pharma industry in the following manner: i.          The initiative aims to support domestic development and manufacturing of high-value biopharmaceutical products and medicines, reduce import dependence, and enhance India’s competitiveness in global biologics supply chain. ii.         Expansion and strengthening of Biopharma-focused network through establishment of three new National Institutes of Pharmaceutical Education & Research (NIPERs) and upgradation of seven existing NIPERs to address growing requirement of specialised human resource in biopharma research, development, manufacturing and regulation. iii.        Creation of large-scale clinical research ecosystem with a focus on improving India’s capacity to conduct advanced clinical trials. iv.        The Central Drugs Standard Control Organisation (CDSCO) to be reinforced to strengthen regulatory framework which will enable faster, globally credible approvals by creation of a dedicated Scientific Review Cadre. It will reduce number of days currently being taken for regulatory approvals. v.         The initiative focuses on early-stage innovation funding and structured equity support to help startups and industry take promising candidates from concept through key development milestones. This information was given by Minister of State for Chemicals and Fertilizers, Smt. Anupriya Patel, in a written reply in the Rajya Sabha today. ***** PC/PM " /> var mPlayer = document.getElementById("background_music"); var mPlayAction = document.getElementById("playbutton"); var isPlaying = false; function playAudio() { mPlayer.play(); isPlaying = true; document.getElementById('stopA').style.display = "block"; document.getElementById('playA').style.display = "none"; } function pauseAudio() { mPlayer.pause(); isPlaying = false; document.getElementById('playA').style.display = "block"; document.getElementById('stopA').style.display = "none"; } //function HandleAudio() { // if (isPlaying == true) { // //Playing already Pause it // pauseAudio(); // } else { // //Play the music // playAudio(); // } //} var synth = window.speechSynthesis; function CleanHtml(html) { html = html.replace(/ /gi, ''); return html; } function stripHtml(html) { let tmp = document.createElement("DIV"); tmp.innerHTML = CleanHtml(html); return tmp.textContent || tmp.innerText || ""; } $(document).ready(function () { //for responsive tables $("table").each(function () { if (!$(this).closest(".table-responsive").length) { $(this).wrap(" "); } }); var width = $(window).width(); if (width $(document).ready(function () { var width = $(window).width(); if (width @media print { .sticky-social, .sticky-social_mb, .pull-right, #printPDF { display: none !important; } } .f_vl { padding-right: 30px; font-size: 17px; cursor: pointer; } .log_oo { // width: 20%; display: flex; justify-content: space-between; } .log_oo img { width: 150px; /*width: 100%; height: auto;*/ } .sticky-social_mb { position: fixed; bottom: 0px; padding: 0px; margin: 0px; width: 100%; } .social_mb { list-style: none; display: flex; width: 100%; margin-bottom: -8px; } .social_mb a { padding: 8px 0px; font-size: 30px; transition: all 0.8s ease-in-out; width: 20% !important; text-align: center; } .section1 { position: relative; padding: 10px 0px; width: 100%; } .sticky-social { position: fixed; top: 20px; left: 0px; padding: 0px; margin: 0px; } .social { list-style: none; } .social a li { padding: 8px 12px; font-size: 25px; transition: all 0.8s ease-in-out; } .social a li:hover { margin-right: -30px; box-shadow: 2px 5px 10px grey; } .social a li:hover .fa { margin-left: 20px; } .fb_b { /* background-color: rgb(59, 89, 152);*/ background-color: rgba(65,103,178,255); } .twitter_r { /* background-color: rgb(29, 161, 242);*/ background-color: #000000; } .whatsapp_r { /* background-color: rgb(77, 194, 71);*/ background-color: rgba(13,191,67,255); } .fa-envelope_r { /* background-color: rgb(219, 68, 55);*/ background-color: #e2123d; } .fa-linkedin_r { background-color: rgb(0, 119, 181); } @media only screen and (max-device-width: 767px) { p span img { max-width: 90% !important; height: auto !important; } p img { max-width: 90% !important; height: auto !important; } h2 { font-size: 20px !important; font-weight: 600 !important; } h3 { font-size: 18px !important; font-weight: 600 !important; } } /* === Film Roll Badge Styling(IFFI2025 countdown) === */ .film-roll-badge { position: absolute; top:82%; right: 20px; width: 230px; height: 70px; background: repeating-linear-gradient( to right, #9a2375 0px, #9a2375 18px, #6e2b8b 18px, #6e2b8b 36px ); border-top: 8px solid #9a2375; border-bottom: 8px solid #9a2375; border-radius: 8px; overflow: hidden; box-shadow: 0 4px 12px rgba(0, 0, 0, 0.4); animation: moveFilm 8s linear infinite; z-index: 10; } /* film sprocket holes */ .film-roll-badge::before, .film-roll-badge::after { content: ""; position: absolute; width: 100%; height: 10px; background: repeating-linear-gradient( to right, #9a2375 0px, #9a2375 10px, #fff 10px, #fff 20px ); left: 0; z-index: 2; } .film-roll-badge::before { top: -4px; } .film-roll-badge::after { bottom: -4px; } .film-roll-inner { position: relative; height: 100%; display: flex; align-items: center; justify-content: center; animation: flicker 2s infinite ease-in-out; } .countdown-text { font-size: 1.3rem; font-weight: 700; color: #fff; text-shadow: 0 0 6px rgba(255, 255, 255, 0.4), 0 0 10px #000; white-space: nowrap; } /* === Animations === */ @keyframes moveFilm { 0% { background-position: 0 0; } 100% { background-position: 120px 0; } } @keyframes flicker { 0%, 100% { opacity: 1; } 50% { opacity: 0.9; } 25% { opacity: 0.95; } 75% { opacity: 0.85; } } /* === Responsive Adjustments === */ @media (max-width: 1500px) { .film-roll-badge { top: 68%; right: 18px; /* width: 220px; */ height: 65px; font-size: 0.85rem; } .press-section { margin-top: 35px; } } @media (max-width: 992px) { .film-roll-badge { top: 52%; right: 10px; width: 200px; height: 60px; } } @media (max-width: 768px) { .film-roll-badge { top: 56%; right: 10px; width: 124px; height: 55px; } .countdown-text { font-size: 0.9rem; } } @media (max-width: 576px) { .film-roll-badge { top: 59%; right: 5px; /* width: 160px; */ height: 50px; } .countdown-text { font-size: 0.85rem; } } const festivalStart = new Date("2025-11-20T00:00:00").getTime(); const festivalEnd = new Date("2025-11-28T23:59:59").getTime(); const countdownElement = document.getElementById("countdown"); const interval = setInterval(() => { const now = new Date().getTime(); // BEFORE FESTIVAL — show days + hours left if (now = festivalStart && now el.style.width = "350px"); clearInterval(interval); } }, 1000); //

Original PIB release
pib.gov.in · PRID 2237416

Open on PIB ↗

Bio Pharma SHAKTI scheme

More from this day